Business Wire

James von Moltke Joins Warburg Pincus

8.9.2026 10:00:00 EEST | Business Wire | Press release

Share

Warburg Pincus, the pioneer of private equity global growth investing, today announced the appointment of James von Moltke as a senior advisor and Executive-in-Residence. Mr. von Moltke, who takes up the role with immediate effect, will bring his extensive industry expertise to support the firm’s European activities with particular focus on the financial and technology sectors, where he will support the identification and evaluation of new potential investment opportunities. He will also play an active role in value creation across the firm’s existing portfolio in Europe.

Mr. von Moltke brings significant industry experience to the firm, having served as President of Deutsche Bank AG since 2022 and as Chief Financial Officer and Member of the Management Board of the Group for nine years. During this time, he played a key role in driving the bank’s transformation, as well as the articulation and execution of Deutsche Bank’s ‘Global Hausbank’ strategy. He also played a lead role in the Initial Public Offering of Deutsche Bank’s asset management affiliate, DWS Group GmbH & Co. KGaA in 2018, and served as Management Board Member responsible for Asset Management from 2023.

Prior to joining Deutsche Bank, he was Treasurer of Citigroup, managing its capital, funding, liquidity and interest rate risk, and also served as the bank’s Head of Corporate M&A and Global Head of Financial Planning and Analysis. Earlier in his career, he led Morgan Stanley's Financial Technology Advisory team globally and spent ten years at J.P. Morgan across New York and Hong Kong, following three years at Credit Suisse First Boston in London.

“Having spent my career at the intersection of global banking, capital markets and financial transformation, I'm excited to bring that experience to Warburg Pincus and its portfolio companies, particularly as the sector navigates a period of significant structural change,” said James von Moltke. “I've long admired Warburg Pincus for its partnership approach, something I saw firsthand in the Primerica IPO, where the firm worked closely with management and the selling shareholder to bring a value-enhancing deal to life.”

“We are delighted to welcome James to Warburg Pincus. He is as seasoned an operator as they come, with a career spanning more than three decades at the top of global financial services,” said Andrew Sibbald, Managing Director, Head of Europe, Warburg Pincus. “James helped lead Deutsche Bank through one of the most consequential transformations in its history, building deep credibility with regulators across the globe along the way. His combination of operating judgment, regulatory credibility and market relationships will be invaluable in helping us source new opportunities and continuing to build value across our portfolio.”

Mr. von Moltke has held numerous advisory and non-executive positions throughout his career, including Chairman of the Deposit Insurance Committee of the Association of German Banks and Vice-Chairman of the Advisory Board of the Prüfungsverband Deutscher Banken e.V. He also represented Deutsche Bank on the boards of the Deutsches Aktieninstitut, Schmalenbach Gesellschaft für Betriebswirtschaft, Atlantik-Brücke e.V. and the American Chamber of Commerce in Germany.

Notes to Editors

About Warburg Pincus

Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $105 billion in assets under management, and more than 225 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.

The firm is headquartered in New York with more than 15 offices globally. For more information, please visit www.warburgpincus.com or follow us on LinkedIn and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908451258/en/

Contacts

Media contact:

Alice Gibb
Director, Europe Communications

Alice.gibb@warburgpincus.com
+44 207 306 3090

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye